Nobel Prize for novel cancer therapies
4 October 2018
Two of the men responsible for the discovery and development of checkpoint inhibitors, therapies that revolutionised the way metastatic melanoma patients are treated, extending lives and improving quality of life for countless patients, were awarded this year’s Nobel Prize in Physiology or Medicine.
Professor James P. Allison from MD Anderson Cancer Centre, and Professor Tasuku Honjo from Kyoto University were jointly awarded the Nobel Prize for their separate work from the early 1990’s, where they each discovered a different protein that plays a major role in regulating the immune system.
The immune system is a balancing act – it is constantly trying to fight off foreign invaders, like viruses and bacteria, without harming the body – that relies heavily on an intricate system of brakes and accelerators. Sometimes the balance is off, resulting in autoimmune diseases where the immune system attacks the body, or diseases like cancer, where the immune system does not recognise that there is anything amiss.
Both Professor Allison and Professor Honjo discovered molecules that act as a brake in the immune system, halting its action and allowing cancers to grow. In Professor Allison’s research, he showed that blocking the molecule he discovered, CTLA-4, could switch off the brake, allowing the immune system to recognise a tumour and attack it. His work lead to the development of the melanoma fighting drug ipilimumab. Professor Honjo discovered the protein PD-1, and found that blocking it allows the immune system to recognise cancer as an invader and mount an immune response. This led to the manufacture of the immunotherapies nivolumab and pembrolizumab.
Ipilimumab, nivolumab and pembrolizumab are now used extensively to treat metastatic melanoma, working to help patient’s own bodies to recognise and fight the disease. Since these treatments have become available, melanoma patients have a better prognosis than ever before.
The two men will receive their Nobel Prizes at a formal ceremony in Stockholm in December. Five different Nobel Prizes are awarded every year, with the Nobel Prize in Physiology or Medicine given to up to three people who have made outstanding discoveries in the fields of medicine or the life sciences. Previous Nobel laureates include three of the men responsible for the discovery of DNA, and the three men who discovered penicillin.
Photograph: Niklas Elmehed/Twitter:NobelPrize
Clinicians and their patients now have access to three online risk calculators developed by researchers at Melanoma Institute Australia.
MIA's Co-Medical Director Professor Richard Scolyer has received The University of Sydney Alumni Award for International Achievement.
More than 120 MIA clinicians, researchers and staff came together online to share research highlights.
For the 2nd consecutive year, MIA's Co-Medical Director Professor Richard Scolyer has been selected in the top 100 best, brightest, and most powerful advocates of pathology by The Pathologist.
As of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own mask.
In a recent issue of Cancer Cell journal, Prof Georgina Long AO and Prof Richard Scolyer discuss the challenge of bringing together clinical work and scientific research to underpin successful cancer research.
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
Professor Long has been appointed as an Officer (AO) of the Order of Australia (General Division) for distinguished service to medicine, particularly, to melanoma clinical and translational research, and to professional medical societies.
“I had a complete response within about six months. All of my tumours disappeared."
‘We are extremely proud of our ongoing contribution to the global effort to save lives from melanoma, with Dr Silva’s prestigious award proof that we continue to lead the way,'
MIA's Co-Medical Director, Professor Richard Scolyer, has achieved a Google Scholar h-index of 100.
We know what Melanoma March means to our community, so when we had to cancel our physical events, we created Melanoma March Virtual so that everyone across Australia could still connect to honour loved ones and support each other.
A must-read personal account by Garry Maddox in The Sydney Morning Herald of how immunotherapy is revolutionising melanoma treatment.
On Friday, a publication that lays out the steps needed to find out if a systematic screening program for melanoma would benefit all Australians was published in the Australia & New Zealand Journal of Public Health.
Melanoma March events have been cancelled. A Virtual March will be held on Sunday 29th March. Read this statement from MIA CEO Matthew Browne.
Thank you to the thousands of Aussies who bought ‘Game On Mole‘ t-shirts, took selfies, shared t-shirt pics on social media and started lifesaving conversations around sun safety and skin health.
Melanoma patients now have greater access to subsidised immunotherapy thanks to additional treatments today being listed on the PBS.
Brisbane couple Leon and Tamra Betts were, like thousands of others around Australia, on the couch watching MAFS when newlywed Natasha ran through her weekly beauty routine. When they heard the 26-year-old mention solarium use, they were shocked, and then saddened, prompting this open letter to all young Australians.
Professor Richard Scolyer, Co-Medical Director of Melanoma Institute Australia, will welcome international attendees this weekend to a sold-out, two-day course on ‘Pigmented Lesions and Other Hot Topics in Dermatopathology’.
It is time for a reality check on solariums.
They have no place in anyone’s beauty routine.